Investor Presentation
|
|
- Jayson Hicks
- 5 years ago
- Views:
Transcription
1 Investor Presentation 1 BSE Symbol : AJANTAPH Code: NSE Symbol : AJANTPHARM ISIN: INE031B01031
2 Safe Harbour Statement This presentation may include certain forward looking statements, based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. The Company disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. 2
3 Index 1. Global Presence 2. India Branded Generics 3. Emerging Markets 4. Regulated Markets 5. Infrastructure 6. Financial Highlights 3
4 Global Presence USA West Asia (3 Countries) CIS (6 Countries) Latin America (4 Countries) South East Asia (3 Countries) India Africa (19 Countries) 4
5 India Branded Generics 5
6 Therapy Focus Dermatology Ophthalmology Cardiology Others MR Strength 2,500 6
7 India Sales Q4 FY 14 Momentum Continues FY14 Sales Rs. 95 Cr (FY13 Rs. 71 Cr) Growth 33% 30 26% 48% % 24 18% Rs. Cr % Ophthalmology Dermatology Cardiology Institution Others Q4 FY'13 Q4 FY'14 7 Source: Company
8 India Sales FY14 Excellent Growth FY14 Sales Rs. 385 Cr (FY13 Rs. 292 Cr) Growth 32% % 45% % Rs. Cr % 32% Ophthalmology Dermatology Cardiology Institution Others FY'13 FY'14 8 Source: Company
9 Within Segments Ajanta Way Ahead 45% 40% 35% 36% 40% 41% 30% 25% 20% 19% 18% 15% 10% 10% 10% 12% 5% 0% Pharma Market Dermatology Cardiology Ophthalmology Source: IMS, MAT March 14 IPM Ajanta Pharma 9
10 Indian Pharmaceutical Market (IPM) v/s Ajanta Growth 40% 35% 38% 36% 30% 29% 25% 20% 15% 15% 10% 10% 10% 5% 0% IPM IPM Indian Pharmaceutical Market, Source: IMS Mar-12 Mar-13 Mar-14 Ajanta Pharma 10
11 Ajanta Branded Generics Sales Evolution Rs. Cr Source: Company
12 IPM Ajanta Improves Rankings Further Segment IMS MAT Mar 14 IMS MAT Mar 13 IMS MAT Mar 05 Ophthalmology Dermatology Cardiology Ajanta Pharma Source: IMS 12
13 IPM Leading Brands, Gaining Ground Brand Value (Rs. Cr) IMS MAT Mar 14 Growth over Previous Year Segment Melacare Range 53 43% Derma Met-XL Range 51 24% Cardio Atorfit Range 32 39% Cardio Softdrops Range 11 83% Ophthal Apdrops Range 9 23% Ophthal Rosufit Range 8 233% Cardio Feburic Range 8 43% Ortho 13 Source: IMS
14 Product Profile Many First To Market Segment Total No. of Products as on today No. of Products First Time in Market (last 9 yrs) Ophthalmology Cardiology Dermatology Others Total Source: Company
15 Ajanta s Brands in Top 100 within Segments Respective Segment No. of Brands in top 100 in respective segment No. of Brands enjoying leadership ( Among Top 3) in respective segment Ophthalmology 7 17 Cardiology 2 6 Dermatology 1 16 Source: Company 15
16 New Product Launches in India Cardio Cardio Derma Derma Ophthal Ophthal Others Others Ophthal FY14 new launches 24 (First to market 9) 16
17 Emerging Markets 17
18 Emerging Markets Brand leadership in many markets 29% Growth in FY 14 & 16% in Q4 FY strong field force in 25+ countries Country specific brand portfolio Expertise in product registrations Fastest growing company in Philippines & Franco Africa Ranked 6 th in Franco & 35 th in Philippines (IMS Dec 13) 18
19 Emerging Markets Q4 Revenue Break-up (Rs. Cr.) % 10% 105 Region Q4 FY14 Q4 FY13 Growth Africa % Asia % Latam % 40 Total % % 0 Africa Asia Latam 19 Q4 FY'13 Q4 FY'14
20 Emerging Markets FY14 Revenue Break-up (Rs. Cr.) % % Region FY14 FY13 Growth Africa % Asia % Latam % Rs. Cr Total % % 16 0 Africa Asia Latam 20 FY'13 FY'14
21 New Product Launches Emerging Markets Region FY 14 Africa 10 Asia 20 Latin America 2 21
22 Emerging Markets Building Brands Region No. of Brands Registered No. of Brands under Registration Field Force Strength Major Segments Africa Antibiotic, Anti-Malaria, Ortho Asia Antibiotic, Derma, Ortho, OTC, Ophthal, Cardio, GI Latam Ophthal, MED, GI Total 1,391 1,
23 Regulated Markets 23
24 Regulated Markets - USA Total ANDAs filed 23 Approved 2 (launched 1) Under approval Approvals expected in FY 15 Own front end team launching Risperidone Filing target every year > 6 Expected market size of ANDA filed $1.5bn (post generic) Only solid dosage Mix of Para II, Para III, Para IV No FTFs 24
25 Infrastructure 25
26 Infrastructure Formulation Manufacturing 3 Facilities in Aurangabad (1 USFDA, UKMHRA, WHO Pre-Q, approved) Total Existing Capacities per annum on single shift basis o Tablets Million o Capsules Million o Powders - 21 Million o Liquids - 8 Million 1 Facility at Mauritius 2 Facilities coming up in Gujarat API Manufacturing 1 Facility in Aurangabad (Captive mid size plant, 18 tons per annum) 26
27 Paithan Manufacturing Facility Approved by US FDA UK MHRA WHO Geneva (Pre-Q) MOH of Multiple Countries Dosage forms Tablets Capsules Powders 27
28 Other Manufacturing Facilities Chitegaon Tablets, Capsules, Oral Jelly Chikalthana Liquid & Oral solids Mauritius Tablet & Capsules API Multi-product facility Mid capacity plant 28
29 New Manufacturing Facilities Under Implementation Dahej Facility Tablet (1,740 Million per annum) Capsule (216 Million per annum) Powder (150 Million per annum) Capacities on single shift basis Commercialization Q1 FY 16 Facility in SEZ Investing Rs.220 Cr, already spent Rs.130 Cr 29 Savli Facility Target completion in Q3 FY16 Ophthal & Derma facility Domestic Tariff Area Investing Rs.180Cr, already spent Rs.15Cr
30 R&D The Catalyst for Growth Formulation, Many first to market products to credit Analytical & API Development Team of 350+ people Niche, complex & difficult to make products Enhancing capacities & capabilities Development of different dosage forms 30
31 R&D Excellent Capabilities Formulation, Expertise in innovative product development Extended Release Bi Layer Doubling the capacity in terms of Space Equipment Other infrastructure Excellent skill set in Drug Regulatory Affairs Dossiers filing Country specific requirements 31
32 Financial Highlights 32
33 Standalone Performance Q4 (Rs. Cr.) Particulars Q4 FY 14 Q4 FY 13 Growth Exports % % to Revenue 66% 71% Domestic % % to Revenue 31% 29% Other Oper. Income 10 0 % to Revenue 3% 0% Revenue % EBITDA % % to Revenue 36% 28% PBT % % to Revenue 31% 24% PAT % % to Revenue 23% 11% 33
34 Standalone Performance FY (Rs. Cr.) Particulars FY 14 FY 13 Growth Exports % % to Revenue 63% 64% Domestic % % to Revenue 35% 35% Other Oper. Income % % to Revenue 2% 1% Revenue % EBITDA % % to Revenue 31% 25% PBT % % to Revenue 28% 19% PAT % % to Revenue 20% 12% 34
35 Consolidated Performance FY (Rs. Cr.) Particulars FY 14 FY 13 Growth Exports % % to Revenue 66% 68% Domestic % % to Revenue 32% 31% Other Oper. Income % % to Revenue 2% 1% Revenue % EBITDA % % to Revenue 31% 24% PBT % % to Revenue 27% 19% PAT % % to Revenue 19% 12% 35
36 Consistent Track Record of Growth 22% CAGR Operating Income 42% CAGR PAT Consolidated Operating Income & PAT (Rs. Cr.) Total Income Profit After Tax 1,
37 Consolidated Performance - FY EBITDA (Rs.Cr.) 369 PAT (Rs.Cr.) Earning Per Share (Rs.) Dividend (Rs. Cr.)
38 Consolidated Key Financial Indicators Rs. Particulars FY 09 FY 10 FY 11 FY 12 FY 13 FY14 EPS Cash EPS EBITDA per share EBITDA margin 19% 19% 20% 22% 24% 31% PAT margin 7% 8% 10% 11% 12% 19% R & D Exp. (Rs. Cr) R & D Exp. (% to Sales) 5% 5% 5% 5% 4% 4% * EPS of all years calculated post bonus shares 38
39 Consolidated Key Financial Indicators Particulars FY 09 FY 10 FY 11 FY 12 FY 13 FY14 Book value per share (Rs.) Dividend/share (Rs.) (FV Rs.5) RONW 16% 18% 22% 26% 28% 39% ROCE 13% 14% 18% 23% 38% 47% Dividend payout 13% 14% 13% 13% 15% 18% * Book Value of all years calculated post bonus shares 39
40 Consolidated Key Financial Indicators Particulars FY 10 FY 11 FY 12 FY 13 FY 14 Long term debt / Equity Total debt/equity Receivable days Inventory days Payable days
41 Growth Drivers India Building on existing brand equity in speciality segments New Segments to gain from enhanced brand equity Pipeline of new product launches Emerging Markets Gaining market share in existing territories Focus on further strengthening the brands New product launches continues Regulated Markets Increased pace of ANDA filings Expected approvals for 3-4 ANDAs in FY 15 Own sales & marketing team in place 41
42 For updates and company information please visit our website: For specific queries, contact: Rajeev Agarwal Ajanta Pharma Limited Ajanta House, Charkop, Kandivli (W), Mumbai
Investor Presentation 2 nd Qtr. - FY 2018
Investor Presentation 2 nd Qtr. - FY 2018 31 st October, 2017 1 of 33 India Disclosure Index 2017 Ajanta s Ranking in Next 100 Listed Companies (Based on Market Cap) 1 st 2 nd 3 rd Voluntary Disclosure
More informationAjanta Pharma Ltd. Rating: BUY. Pharmaceuticals. Ajanta Pharma STOCK IDEA
Ajanta Pharma Ltd Pharmaceuticals Date July 8, 215 CMP (Rs.) 1594 Target (Rs.) 19 Potential Upside 19% BSE Sensex 27688 NSE Nifty 8363 Scrip Code Bloomberg AJP IN Reuters AJPH.BO BSE Group A BSE Code 532331
More informationAjanta Pharma Ltd l Management Meet Note 4th November 11
Stock Code BSE Code 532331 BSE Group B Bloomberg AJP IN Reuters AJPH.BO Market Data CMP (Rs) 335 Target Price (Rs) NOT RATED Potential Upside (%) - Market Cap (Rs Cr) 390 52 Wk High/Low (Rs) 368/172 Shareholding
More informationajanta pharma limited
ajanta pharma limited Recommendation BUY CMP (08 April 2011) Rs. 209 Target Price Rs. 295 Sector Pharmaceuticals Stock Details BSE Code NSE Code Bloomberg Code Market Cap (Rs cr) Free Float (%) 52- wk
More informationAjanta Pharma Ltd. COMPANY REPORT BUY. Summary. Investment Highlights. In top gear. Nifty: 6,493; Sensex: 21,775
Mar/13 Apr/13 May/13 Jun/13 Jul/13 Aug/13 Sep/13 Oct/13 Nov/13 Dec/13 Jan/14 Feb/14 Mar/14 COMPANY REPORT March 14, 2014 Ajanta Pharma Ltd. In top gear BUY Nifty: 6,493; Sensex: 21,775 CMP Target Price
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationPRESS MEET Q4 & FY14. Dr. Reddy s Laboratories Limited May 13, Dr. Reddy's Laboratories Limited. All Rights Reserved.
Dr. Reddy s Laboratories Limited May 13, 2014 Q4 FY 14 Business Highlights Sales Gross Profit 3,481 Cr 4.2 % 57.2 % 18 % YoYGr% to sales YoYGr% R & D Adj. EBITDA 11.4 % 71 % 22.8 % 2 %* to sales YoYGr%
More informationQ4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017
Q4 FY16-17 EARNINGS PRESENTATION 29 th May 2017 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationQ3 FY17-18 EARNINGS PRESENTATION. 7 th February 2018
Q3 FY17-18 EARNINGS PRESENTATION 7 th February 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationIPCA Laboratories Ltd 26 th August, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY IPCA Laboratories Ltd 26 th August, 2013 BUY CMP(As on 24/8/13) Rs.623.30 Target Price Rs.780.00 BSE Code 524494 NSE Code IPCALAB Market
More informationCanara Bank Securities Ltd
A WHOLLY OWNED SUBSIDIARY OF CANARA BANK Ajanta Pharma (IC) LTP : 1481 Date :26 th Dec 2017 Stock Info Sector Market Target 1728 Holding Period Pharmaceuticals & Drugs Domestic & International 9-11 months
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation July-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationAlembic Pharmaceuticals Ltd
Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe
More informationLupin Limited Corporate Presentation. May 2009
Lupin Limited Corporate Presentation May 2009 Corporate Highlights Eleventh successive quarter of growth in sales and profits. Growth has been secular across SBUs and regions Particularly strong in US,EU,
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15. Revenue figures
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15 Revenue figures (` In Lacs) Unaudited Audited Particulars July 14 Sept. 14 Quarter Ended Apr. 14 Jun. 14 July 13 Sept.
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationCadila Healthcare Ltd.
Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 s. Cadila Healthcare Ltd.. August 8, 216 BSE Code: 532321 NSE Code: CADILAHC Reuters Code: CADI.NS Bloomberg Code:
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation May-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationQ2 FY18-19 EARNINGS PRESENTATION
Q2 FY18-19 EARNINGS PRESENTATION 12 th November 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationInvestor Presentation Q2FY
Investor Presentation Q2FY19 05-11-2018 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking
More informationFY12 FY13 FY14E FY15E
Initiating Coverage Unichem Laboratories Attractive valuation with a strong Balance Sheet Unichem laboratory (ULL), an integrated pharmaceutical company has a strong footprint in domestic formulation market.
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationAlembic Pharmaceuticals Ltd. Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation October-2016 Contents 1. Milestones 2. Quarterly Highlights 3. Half yearly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials
More informationQ4 FY17-18 EARNINGS PRESENTATION
Q4 FY17-18 EARNINGS PRESENTATION 28 th May 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationLUPIN LIMITED. Q2 FY17 Investor Presentation November 09, Aerial view of Lupin offices, Baltimore, US
LUPIN LIMITED Q2 FY17 Investor Presentation November 09, 2016 Safe Harbor Statement This report contains forward-looking statements that involve known and unknown risks, uncertainties and other factors
More informationAjanta Pharmaceuticals (AJAPHA) 1543
Result Update Rating matrix Rating : Buy Target : 178 Target Period : 15-18 months Potential Upside : 15% What s Changed? Target Unchanged EPS FY16P Changed from 44.1 to 45.7 EPS FY17E Changed from 49.3
More informationAlembic Pharmaceuticals Ltd 25 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Alembic Pharmaceuticals Ltd 25 th September, 2012 CMP Target Price Rs.70.85 Rs.90.00 Alembic Pharma continues to maintain its market share
More informationQ3 FY09 Results Update
Q3 FY09 Results Update January 20, 2009 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16. Apr Mar. 15 Net Sales : Jan. 15 Mar. 15
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16 Financials (` In Lacs) Unaudited Audited Particulars Quarter Ended Year Ended Apr. 15 Jun. 15 Jan. 15 Mar. 15 Apr. 14
More informationPress Release. Consolidated Financial & Performance Highlights (Pharma & Biotech)
Press Release Strides Shasun announces Q1 FY17 results Q1 FY17 Pharma Revenues* at INR 8,699 Mn, Growth of 43% YoY, Pharma EBITDA at INR 1,451 Mn, Growth of 57% YoY Bengaluru, August 17, 2016: Strides
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More informationJ.B. Chemicals & Pharmaceuticals Ltd.
Oct-16 Nov-16 Nov-16 Dec-16 Jan-17 Jan-17 Feb-17 Mar-17 Apr-17 Apr-17 May-17 Jun-17 Jun-17 Jul-17 Aug-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 146 J.B. Chemicals & Pharmaceuticals Ltd. October
More informationAjanta Pharmaceuticals (AJAPHA) 1701
Result Update Rating matrix Rating : Buy Target : 196 Target Period : 12-15 months Potential Upside : 12% What s Changed? Target Changed from 222 to 196 EPS FY17E Changed from 57.6 to 59.7 EPS FY18E Changed
More informationAjanta Pharmaceuticals (AJAPHA) 2560
Result Update Rating matrix Rating : Buy Target : 322 Target Period : 12-15 months Potential Upside : 26% What s Changed? Target Changed from 2151 to 322 EPS FY16E Changed from 85.5 to 13.7 EPS FY17E Changed
More informationAjanta Pharmaceuticals (AJAPHA) 1701
Result Update Rating matrix Rating : Hold Target : 178 Target Period : 12-15 months Potential Upside : 5% What s Changed? Target Unchanged EPS FY16 Changed from 45.7 to 45.4 EPS FY17E Changed from 52.4
More informationBUY AJANTA PHARMA LTD. CMP Target Price JAN. 28 th 2014 SYNOPSIS. Result Update: Q3 FY14
BUY CMP 940.00 Target Price 1025.00 AJANTA PHARMA LTD. Result Update: Q3 FY14 JAN. 28 th 2014 ISIN: INE031B01031 Index Details Stock Data Sector Pharmaceutical BSE Code 532331 Face Value 5.00 52wk. High
More informationDr. Reddy s Laboratories Ltd Q3 FY12 Press Meet. February 03, 2012
Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet February 03, 2012 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationBDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 538.15 Target Price 592.00 TORRENT PHARMACEUTICALS LTD Result Update: Q3 FY14 JANUARY 25 th 2014 ISIN: INE685A01028 Index Details Stock Data Sector Pharmaceuticals BSE Code 500420 Face Value 5.00
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationLincoln Pharmaceuticals Limited
25 January 2016 CMP: Rs.219.5 Industry: Healthcare BSE Group/Index: B/ Promoters Patel family Year of incorporation 1995 Registered office Lincoln House, B/h Satyam Complex, Science City Road, Viilage
More informationBiocon Limited Announces Results for the Nine Months Ended December 31, 2009
Bangalore, January 21, 2010 India Biocon Limited Announces Results for the Nine Months Ended December 31, 2009 Revenues at Rs 1,739 crores; EBITDA at Rs 369 crores; PAT at Rs 213 crores. Commenting on
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationFinancials/Valu FY15 FY16 FY17 FY18E FY19E. Approval of glialda, a significant milestone:cadila received approval 155
Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 15-Nov-17 INDUSTRY - Pharmaceuticals BLOOMBERG- CDH IN BSE Code - 532321 NSE Code - CADILAHC NIFTY - 10186 Company
More informationRanbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec 14 Sales Rs.81,778 Mn
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationFY2017 FY2018E FY2019E
Jul-12 Dec-12 May-13 Oct-13 Mar-14 Aug-14 Jan-15 Jun-15 Nov-15 Apr-16 Sep-16 Feb-17 Jul-17 2QFY2018 Result Update Pharmaceutical November 20, 2017 Lupin Performance Highlights Y/E March (`cr) 2QFY2018
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationLupin 1QFY2018 Result Update
Jul-12 Nov-12 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Mar-15 Jul-15 Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 1QFY2018 Result Update Pharmaceutical August 07, 2017 Lupin Performance Highlights Y/E March
More informationPress Presentation Q1 FY19
1 July 26, 2018 Q1 FY19 Press Meet Press Presentation Q1 FY19 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationPromising growth trajectory. Ajanta Pharma
Initiating Coverage 17 March 2017 Sector: Healthcare Ajanta Pharma Domestic: Aggressive launches, improving MR productivity USA: Healthy pipeline, manufacturing capacity, front end Promising growth trajectory
More informationDr Reddy s Laboratories Ltd. Q1 FY05 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 04 Branded Formulations
More informationAurobindo Pharma Ltd Q1 FY18-19 Financial Results Q1 Q1
NEWS RELEASE 9 th August 2018, Hyderabad, India Consolidated financial results Q1FY18-19 Aurobindo Pharma Ltd Q1 FY18-19 Financial Results Amount in INR Cr Q1 Q1 Q4 FY18-19 FY17-18 FY17-18 Revenue from
More informationJUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS
PRESS RELEASE Noida, Saturday, Oct 28, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS The Board
More informationLupin NEUTRAL. Performance Highlights. CMP `1,838 Target Price - 2QFY2016 Result Update Pharmaceutical. Investment Period -
2QFY2016 Result Update Pharmaceutical November 10, 2015 Lupin Performance Highlights Y/E March (` cr) 1QFY2016 4QFY2015 % chg qoq 1QFY2015 % chg yoy Net sales 3,178 3,074 3.4 3,117 2.0 Other income 184
More informationJUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS
PRESS RELEASE Noida, Monday, Oct 22, 2018 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS JUBILANT
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationAlembic Pharmaceuticals Limited Investors Update Q3FY12
Alembic Pharmaceuticals Limited Investors Update Q3FY12 Quarter ended 31 st December 2011 Net sales up 15% at Rs 382 crores against Rs. 331 crores in corresponding quarter last year Domestic formulations
More informationMargin (%) PAT (Rs cr)
4 Recommendation HOLD Reiterating positive outlook CMP (27/7/2015) Rs. 115 Target Price Rs. 125 Sector Stock Details Pharmaceuticals BSE Code 532482 NSE Code Bloomberg Code GRANULES GRAN IN Market Cap
More informationLupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart
2QFY2017 Result Update Pharmaceutical November 11, 2016 Lupin Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg qoq 2QFY2016 % chg yoy Net sales 4,212 4,316 (2.4) 3,193 31.9 Other income
More informationPioneers of laminated tubes in India. Corporate Presentation
Pioneers of laminated tubes in India Corporate Presentation M17617 Safe Harbour Certain statements in this presentation concerning our future growth prospects are forward-looking statements. The Company
More informationHardick Bora QFY13 Results Update Sector: Healthcare Lupin CMP: INR725 TP: INR851 Buy
BSE Sensex S&P CNX 19,990 6,069 Bloomberg LPC IN Equity Shares (m) 447.6 M.Cap. (INR b)/(usd b) 324.5/6.0 52-Week Range (INR) 739/507 1,6,12 Rel. Perf. (%) 9/18/13 Financials & Valuation (INR b) Y/E March
More informationInvestor Presentation
Aurobindo Pharma Limited Investor Presentation Investor Presentation August 2015 May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY14
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY14 Revenue figures (Stand Alone) Particulars Un-audited Audited Quarter Ended Year Ended 30.06.13 31.03.13 30.06.12 % Gwth
More informationQ3 FY15-16 Unaudited Financials
NEWS RELEASE 9 th February 2016, Hyderabad, India Q3 Unaudited Financials Amount in INR Cr Q3 Q3 % Chg Q2 % Chg 9 Months FY14-15 (YoY) (QoQ) Consolidated Net Operating Income* 3,495.5 3,166.2 10.4 3,333.5
More informationNATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza,
(? AUROBINDO Date: November 12, 2018 To To NATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza, 25 th floor, Dalal Street, Sandra Kurla Complex, Sandra (E), MUMBAI
More informationDr Reddy s Laboratories Ltd. Q4 FY07 and FY07 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Q4 and Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 05 Branded
More informationQ4 18 and FY18 Investor Presentation
Q4 18 and FY18 Investor Presentation Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements
More informationDr. Reddy s Q3 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) CONTACT MEDIA
More informationBird s Eye View of Indian Pharma
Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy
More informationDr. Reddy s Q4 and FY18 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationPFIZER LIMITED Result Update (PARENT BASIS): Q1 FY15
PFIZER LIMITED Result Update (PARENT BASIS): Q1 FY15 ISIN: INE182A01018 SEPTEMBER 29 th,2014 Recommendation BUY CMP 1634.05 Target Price 1797.00 STOCK DETAILS Sector BSE Code 500680 Face Value 10.00 Pharmaceuticals
More informationDr. Reddy s Q1 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationPress Presentation- Q3 FY17. February 4th, 2017
Press Presentation- Q3 FY17 February 4th, 2017 Q3 Dr. FY17 Reddy s Press meet Laboratories Limited 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve
More informationWarm Welcome Shareholders. 22nd Annual General Meeting June 10, 2013
Warm Welcome Shareholders 22nd Annual General Meeting June 10, 2013 Performance Snapshot - FY 2012 Revenue * EBITDA * 31% 36% 2291 INR Crores (Except EPS) 562 1748 413 904 920 1188 104 159 320 2008 2009
More informationJenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /
More informationPress Presentation Q4 18 & FY18
1 May 22, 2018 Q4 FY18 Press Meet Press Presentation Q4 18 & FY18 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationPlan. Prepare. Perform Annual Report
Plan. Prepare. Perform. 2016-17 Annual Report Table of Contents 01-17 Corporate Overview 01 Plan. Prepare. Perform. 17 Corporate Information Turnover `2,000+ cr. 18-62 Statutory Reports 18 Management Discussion
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationAsian Oilfield Services Limited
23 December 2015 CMP: Rs.63.2 Industry: Oil and Gas BSE Group/Index: XD Promoters Samara Capital Partners Fund Year of incorporation 1992 Registered office 703, IRIS Tech Park, Tower-A, 7th Floor, Sector
More informationAurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months
Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 Nov-17 Mar-18 Jul-18 Nov-18 2QFY2019 Result Update Pharmaceutical November 17, 2018 Aurobindo Pharma Performance Highlights Y/E march (` cr) 2QFY19 1QFY19 % chg
More informationPress Meet Q3 FY16. February 9, Dr. Reddy s Laboratories Limited.
Press Meet Q3 FY16 February 9, 2016 Dr. Reddy s Laboratories Limited. Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationCD Equisearch Pvt Ltd June 5 th, 2015
June 5 th, 2015 J B Chemicals & Pharmaceuticals Ltd. No. of shares (crore) 12.82 Mkt cap (Rs crs) 2962 Current Price (6/4/2015) 231 Price Target 288 52 week H/L (Rs.) 268.50/140.00 Book Value (Rs) (FV
More informationNavin Fluorine International Limited
Navin Fluorine International Limited Result Update Presentation FY18 Safe Harbor This presentation and the accompanying slides (the Presentation ), which have been prepared by Navin Fluorine International
More informationGranules India Ltd. 21 st July, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Granules India Ltd. 21 st July, 2012 CMP Target Price Rs.149.30 Rs.200.00 Granules India is among the leading global manufacturer of highvolume
More informationHIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing
More informationAurobindo Pharma Ltd.
. Volume No.. I Issue No. 165 Aurobindo Pharma Ltd. March 12, 2018 BSE Code: 524804 NSE Code: AUROPHARMA Reuters Code: ARBN.NS Bloomberg Code: ARBP:IN Aurobindo Pharma Ltd (Auro) is one of the largest
More informationDr. Reddy s Q3 and 9M FY18 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CIN: L85195TG1984PLC004507 INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph:
More informationHOLD. Sun Pharmaceutical Industries Ltd. Pharmaceuticals RETAIL EQUITY RESEARCH. CMP Rs. 571 TARGET Rs. 597 RETURN 5% 19 th June, 2018 COMPANY UPDATE
COMPANY UPDATE RETAIL EQUITY RESEARCH Sun Pharmaceutical Industries Ltd. Pharmaceuticals BSE CODE: 524715 NSE CODE: SUNPHARMA Bloomberg CODE: SUNP:IN SENSEX: 35,548 HOLD Rating as per Large Cap 12 months
More informationBUSINESS UPDATE Scaling new heights EBITDA and PAT at record levels Revenue up 22% YoY EBITDA up 29% and PAT up 31% YoY Cash PAT up 37% Mumbai, Januar
BUSINESS UPDATE Scaling new heights EBITDA and PAT at record levels Revenue up 22% YoY EBITDA up 29% and PAT up 31% YoY Cash PAT up 37% Mumbai, January 29, 2015: Welspun India Ltd., (WIL), part of the
More informationNavin Fluorine International Limited
Navin Fluorine International Limited Result Update Presentation Q3 & 9M FY18 Safe Harbor This presentation and the accompanying slides (the Presentation ), which have been prepared by Navin Fluorine International
More informationDISCUSSION SUMMARY. Q1 FY15 Results Highlights About Us Q1 FY15 Consolidated Financials 14. Business Strategy & Outlook 17
DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q1 FY15 QUARTERLY INVESTOR UPDATE AUGUST 2014 DISCUSSION SUMMARY Q1 FY15 Results Highlights 04 08 About Us 09 13 Q1 FY15 Consolidated Financials 14 Business
More informationDr. Reddy s Q1 FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationFinancials/Valuation. 1Mn 3Mn 1Yr P/B (X) Absolute (7.8) (6.3) (5.3) P/E (x) Rel.to Nifty (6.5) (8.6) (25.0) Recent Developments:
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 08-Feb-18 Bloomberg- INDUSTRY - CIPLA IN BSE Code - 500087 NSE Code - NIFTY - PHARMACEUTICAL CIPLA 10476 Comapany
More informationINOX WIND LIMITED Q2FY18 INVESTOR UPDATE
INOX WIND LIMITED Q2FY18 INVESTOR UPDATE DISCLAIMER This presentation and the following discussion may contain forward looking statements by Inox Wind Limited ( IWL or the Company ) that are not historical
More informationORIENTAL CARBON & CHEMICALS LTD. Providing Solutions Creating Innovations
ORIENTAL CARBON & CHEMICALS LTD Providing Solutions Creating Innovations Investor Presentation May 2018 Safe Harbor This presentation and the accompanying slides (the Presentation ), which have been prepared
More informationGlenmark Pharmaceuticals Ltd 23 rd May, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Glenmark Pharmaceuticals Ltd 23 rd May, 2012 CMP(As on 22/5/2012) Rs.357.00 Target Price Rs 450.00 As per ORG IMS MAT March 2012 data,
More informationFinancial Results Analysis Quarter & Half Year Ended September 30, 2011
Financial Results Analysis Quarter & Half Year Ended September 30, 2011 Disclaimer 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements
More information